Astellas/UMN Complete Inoculations In Phase III Seasonal Influenza Vaccine Study
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharmaceuticals and UMN Pharma have completed the inoculation of all subjects in a Phase III trial for ASP7374, a cell culture seasonal influenza vaccine, the companies announced Dec. 11.